OakChart

Sunshine Biopharma Inc

SBFMHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.75-0.10 (-3.51%)
2026-11-12 02:01 CET
Market cap
2.17 USD m
Revenue, TTM
35.35 USD m
Net income, TTM
-5.83 USD m
Free cash flow, TTM
-5.35 USD m
EPS diluted, TTM
-204.52
P/E
-
Compare

Price

SBFM against its 20, 50 and 200-day averages
2050200earnings
0.00200.00400.004.4M8.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SBFMclose 2.7520-day 3.2950-day 10.85200-day 99.252.7552w high

99.4% under the 52-week high of 464.00 on 18 May 2026. 52-week low 2.53 on 5 Nov 2026. Last 15 sessions, 50.2% high to low

Volume 0.18× normal · the line is the 50-bar volume average

Profile

SBFM
52-week range, 0% of the way up
2.53464

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

Employees50
IPOOct 30, 2009
Beta1.50
ATR, 14d0.99
Rel volume0.18
Short float103.71%
Inst own7.57%

Snapshot

6 groups

Valuation

Index-
Market Cap2.09M
Enterprise Value-10.97M
Income-5.83M
Sales35.35M
Book/sh230.48
Cash/sh18.06
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees50
IPOOct 30, 2009

Ratios

P/E-
Forward P/E-
PEG-
P/S0.06
P/B0.01
P/C0.15
P/FCF-
EV/EBITDA-
EV/Sales-0.31
Quick Ratio3.30
Current Ratio5.46
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-204.52
EPS next Y-8.00
EPS next Q-3.40
EPS this Y86.46%
EPS next Y79.49%
EPS next 5Y-
EPS past 3/5Y92.58% 80.76%
Sales past 3/5Y102.91% 247.73%
EPS Y/Y TTM60.85%
Sales Y/Y TTM-2.74%
EPS Q/Q70.91%
Sales Q/Q-1.56%
EarningsAug 05
EPS/Sales Surpr.4.17% 6.90%

Ownership

Insider Own-
Insider Trans-
Inst Own7.57%
Inst Trans-
ROA-17.78%
ROE-21.92%
ROIC-20.82%
Gross Margin29.31%
Oper. Margin-14.71%
Profit Margin-16.50%
SMA20-16.53%
SMA50-74.66%
SMA200-97.23%
Trades-

Technical

Shs Outstand0.76M
Shs Float0.17M
Short Float103.71%
Short Ratio0.60
Short Interest0.18M
52W High464.00 -99.41%
52W Low2.53 8.70%
Volatility8.51% 15.57%
ATR (14)0.99
RSI (14)28.41
Beta1.50
Rel Volume0.18
Avg Volume294.53K
Volume52,868

Performance

Perf Week3.77%
Perf Month-41.81%
Perf Quarter-88.54%
Perf Half Y-97.92%
Perf YTD-98.88%
Perf Year-99.21%
Perf 3Y-100.00%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom1.00
Target Price1120.00
Prev Close2.85
Price2.75
Change %-3.51%

Peers

Mkt cap
TickerCompanyMkt cap
AMRXAmneal Pharmaceuticals Inc7.56B
AMPHAmphastar Pharmaceuticals Inc1.22B
VTRSViatris Inc24.14B
TEVATeva- Pharmaceutical Industries Ltd50.45B
CPIXCumberland Pharmaceuticals Inc91.70M
RDYDr. Reddy's Laboratories Ltd ADR12.36B
RDHLRedhill Biopharma Ltd ADR3.25M
HROWHarrow Inc1.10B
SNOASonoma Pharmaceuticals Inc5.94M
UPCUniverse Pharmaceuticals INC7.89M

News

latest 14 of 200
  • Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing (ACCESSWIRE) -22.47%
  • Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering (ACCESSWIRE) -21.44%
  • Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns (InvestorsHub) -38.57%
  • Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering (ACCESSWIRE)
  • Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio (ACCESSWIRE) -8.64%
  • Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies (ACCESSWIRE)
  • Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions (ACCESSWIRE)
  • Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer (ACCESSWIRE) +8.77%
  • Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market (ACCESSWIRE)
  • Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market (ACCESSWIRE) -12.14%
  • Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval (ACCESSWIRE) +11.97%
  • Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting (ACCESSWIRE) -6.54%
  • Sunshine Biopharma and University of Arizona Publish Significant New Research Findings (ACCESSWIRE)
  • Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R) (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-05-23.000-24.000-22.9119.308.701
2026Q12026-05-13-50.000-50.000-50.7088.098.091
2025Q42026-02-25-60.000-54.000-92.1048.5810.001
2025Q32025-11-11-38.000-26.000-38.7989.4211.101
2025Q22025-07-30-78.000-22.000-78.7729.4111.201
2025Q12025-05-15-88.000--87.2848.90--
2024Q32024-11-06-188-107,000-188.998.4411.801
2024Q22024-08-19-1,988-120-1,9889.309.001
2024Q12024-05-08-8,000-32,000-8,0087.547.001
2023Q42024-03-28-20,000-12,000-20,9327.686.101
2023Q32023-11-14-16,000-24,000-10,1445.966.001
2023Q22023-08-10-8,000-32,000-14,2365.565.001
2023Q12023-08-04-32,000--30,9044.90--
2024Q4--2.000-167.3-12.501
2026Q3---3.400--9.601
2026Q4---5.800--9.801

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-76,000-64,000-74,07624.0922.51
2024FY-1,464-824-1,46334.8737.80
2025FY-288-202-36.3037.73
2026FY--39.000--35.80
2027FY--8.000--45.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-011009.609.609.60
2026Q3S2026-08-181109.609.609.60
2026Q3S2026-08-051009.109.109.10
2026Q3S2026-07-281009.109.109.10
2026Q3S2026-07-271009.109.109.10
2026Q3S2026-05-141019.109.109.10
2026Q3S2026-05-131019.109.109.10
2026Q3S2026-04-071009.909.909.90
2026Q3E2026-11-01100-3.40-3.40-3.40
2026Q3E2026-08-18110-3.40-3.40-3.40
2026Q3E2026-08-05100-4.00-4.00-4.00
2026Q3E2026-07-29100-4.00-4.00-4.00
2026Q3E2026-07-27100-0.20-0.20-0.20
2026Q3E2026-05-15110-4.00-4.00-4.00

Estimate history

EPS, annual-38080000-56640000-7904000-1091200-380892800-704688-74076-1463.234-287.478-204.521
Period201720182019202020212022202320242025TTM
EPS, quarterly-1988.08-188.992-167.296-87.284-78.772-38.798-92.104-50.708-22.911
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000.0210.0710.2284.34624.09334.87436.30635.35
Period201720182019202020212022202320242025TTM
Sales, quarterly9.3038.4359.5958.9019.419.4178.5778.0899.264
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00000000.0130.0250.119
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0060.010.0130.0140.0230.0230.0250.0250.119
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue35.3536.3134.8724.094.350.230.070.020.00
Cost of Goods Sold Incl. D&A24.9924.3824.4315.902.670.130.040.020.05
Gross Profit10.3611.9210.458.191.670.100.03-0.00-0.05
Selling, General and Administrative Excl. Other15.0415.9315.8712.6910.292.540.610.641.11
Research and Development0.240.600.931.860.810.670.060.020.01
Other Operating Expense0.510.470.390.290.060.000.000.000.00
Operating Income-5.20-4.48-5.81-4.79-8.67-2.44-0.58-0.64-1.16
Interest Expense0.000.000.010.140.040.330.170.120.14
Unusual Expense0.691.750.000.0018.329.672.050.310.87
Net Income Before Taxes-5.56-5.95-5.37-4.11-26.51-12.44-2.78-1.08-2.14
Income Taxes0.270.02-0.230.400.230.000.000.000.00
Consolidated Net Income-5.83-5.98-5.13-4.51-26.74-12.44-2.78-1.08-2.14
Net Income From Continuing Operations-5.83-5.98-5.13-4.51-26.74-12.44-2.78-1.08-2.14
Net Income-5.83-5.98-5.13-4.51-26.74-12.44-2.78-1.08-2.16
EPS (Recurring)-78.40-228.60-1,463.23-74,076.30-366,865.27-173,634,471.67-529,628.76-6,339,626.81-40,586,684.17
EPS (Basic, Before Extraordinaries)-204.52-287.48-1,463.23-74,076.00-704,688.00-380,892,800.00-1,091,200.00-7,904,000.00-56,640,000.00
EPS (Diluted)-204.52-287.48-1,463.23-74,076.00-704,688.00-380,892,800.00-1,091,200.00-7,904,000.00-56,640,000.00
EBITDA-4.85-4.15-5.59-4.64-8.65-2.43-0.56-0.63-1.11
Non-Operating Income (Expense)0.320.270.450.810.525E-050.01-0.020.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Price To Earnings Ratio----0.010.26---
Price To Sales Ratio0.080.140.060.272.240.6744.874.662.18
Gross Margin29.3132.8429.9533.9938.4642.8444.11-17.53-
Operating Margin-14.71-12.34-16.67-19.86-199.60-1,068.24-807.83-3,037.91-
Net Margin-16.50-16.46-14.72-18.70-615.44-5,444.41-3,898.74-5,114.18-
Shares Outstanding0.120.020.010.000.000.000.000.000.00
Market Capitalization2.172.177.746.9712.090.155.440.321.37

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue9.268.098.589.429.418.909.598.44
Cost of Goods Sold Incl. D&A6.915.985.656.446.066.246.575.63
Gross Profit2.352.102.932.983.352.673.032.80
Selling, General and Administrative Excl. Other3.823.374.463.394.233.964.683.91
Research and Development0.010.030.070.120.200.220.150.13
Other Operating Expense0.140.130.130.120.110.000.390.00
Operating Income-1.61-1.40-1.66-0.53-0.99-1.30-2.04-1.11
Interest Expense0.000.000.000.000.000.000.01-
Unusual Expense0.000.000.130.551.060.000.000.00
Net Income Before Taxes-1.56-1.24-1.73-1.02-1.98-1.22-2.29-0.98
Income Taxes0.000.000.41-0.14-0.21-0.04-0.130.22
Consolidated Net Income-1.56-1.24-2.14-0.88-1.77-1.18-2.16-1.20
Net Income From Continuing Operations-1.56-1.24-2.14-0.88-1.77-1.18-2.16-1.20
Net Income-1.56-1.24-2.14-0.88-1.77-1.18-2.16-1.20
EPS (Recurring)-22.91-50.71-88.14-21.75-45.71-87.28-167.30-188.99
EPS (Basic, Before Extraordinaries)-22.91-50.71-92.10-38.80-78.77-87.28-167.30-188.99
EPS (Diluted)-22.91-50.71-92.10-38.80-78.77-87.28-167.30-188.99
EBITDA-1.53-1.32-1.56-0.44-0.92-1.23-1.97-1.04
Non-Operating Income (Expense)0.050.150.060.070.070.08-0.240.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio0.080.140.160.180.180.140.220.12
Gross Margin25.3526.0134.1631.6235.6029.9531.5533.21
Operating Margin-17.41-17.25-19.33-5.65-10.55-14.56-21.24-13.12
Net Margin-16.88-15.38-24.96-9.39-18.82-13.25-22.49-14.20
Shares Outstanding0.120.020.020.020.020.010.010.01
Market Capitalization2.095.106.036.796.565.177.746.36

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments9.129.6916.2921.832.050.990.040.110.11
Short Term Receivables3.463.872.551.910.010.000.000.000.00
Inventories13.4711.285.733.290.110.020.020.000.00
Other Current Assets0.801.130.310.280.040.010.010.990.01
Total Current Assets26.8525.9724.8927.312.201.030.071.100.12
Net Property, Plant & Equipment1.341.481.011.150.010.020.030.050.06
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets1.893.021.440.780.000.000.000.000.00
Deferred Tax Assets0.000.09-0.30-----
Other Assets0.000.000.000.000.000.000.000.000.08
Total Assets30.0830.5627.3529.552.201.050.101.150.26
Short Term Debt Incl. Current Port. of LT Debt0.220.210.120.120.000.960.720.660.72
Accounts Payable5.665.542.592.800.040.060.100.120.00
Income Tax Payable0.270.270.300.37-----
Other Current Liabilities0.300.302.553.630.050.020.020.130.03
Total Current Liabilities6.446.315.556.930.091.050.830.910.75
Long Term Debt0.600.740.540.641.900.950.000.000.08
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities--0.050.34-----
Other Liabilities0.000.000.000.000.000.000.000.290.00
Total Liabilities7.047.066.147.921.992.000.831.200.83
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.010.010.000.000.100.100.050.050.05
Common Equity23.0323.4921.2121.630.11-1.05-0.79-0.11-0.62
Total Shareholders Equity23.0423.5021.2121.630.21-0.95-0.74-0.06-0.57
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity23.0423.5021.2121.630.21-0.95-0.74-0.06-0.57
Total Liabilities & Stockholders Equity30.0830.5627.3529.552.201.050.101.150.26
Book Value Per Share938.681,820.69302,685.43383,014.653,447,422.04-243,597.75-1,778,901.98-1,975,583.78-21,712,399.86
Tangible Book Value Per Share861.651,586.61282,071.03369,256.243,447,422.04-243,597.81-1,778,901.47-1,975,583.78-21,712,399.86
Full-Time Employees50524446333123
Price to Book Ratio0.010.330.320.301.36-5.16-0.40-12.96-27.07
Return on Assets-19.71-17.73-15.84-168.48-765.71-486.89-173.22-304.54-646.33
Return on Equity-25.68-22.97-21.04-244.92-----
Return on Invested Capital-25.28-21.18-20.72-120.09-588.94----
Quick Ratio2.082.333.453.4722.910.950.061.210.16
Current Ratio4.174.114.483.9424.070.980.081.210.16

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-5.83-5.98-5.13-4.51-26.74-12.44-2.78-1.66-2.16
Depreciation0.350.330.220.150.030.010.010.010.05
Other Funds (Non Cash)0.791.760.010.0018.3210.702.161.181.54
Funds from Operations-4.69-3.88-4.90-4.36-8.40-1.72-0.61-0.46-0.57
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.64-1.45-7.63-4.423.15-0.11-0.04-0.030.05
Income Taxes Payable0.010.00-0.81-0.070.24----
Cash from Operating Activities-5.33-5.33-12.52-8.78-5.25-1.83-0.66-0.50-0.51
Capital Expenditures-0.18-0.84-1.98-0.79-0.300.00-0.00-0.00-0.02
Net Assets From Acquisitions0.000.000.000.00-14.350.000.000.000.00
Sale of Fixed Assets and Businesses-0.090.000.000.130.030.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-0.000.000.00-0.010.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.28-0.84-1.98-0.66-14.620.00-0.00-0.02-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.534.758.943.5543.460.000.000.000.00
Repurchase of Common Pref Stock0.000.00-3.14-0.54-0.100.000.000.000.00
Sale of Common Pref Stock8.534.7512.084.0943.560.000.000.000.00
Proceedsfrom Stock Options5.081.838.520.5930.370.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00-3.962.901.610.440.53
Change in Long Term Debt0.000.000.000.00-3.962.901.610.440.53
Issuance of Long Term Debt0.000.000.000.000.003.381.710.500.72
Reduction of Long Term Debt0.000.000.000.00-3.96-0.48-0.11-0.05-0.19
Net Financing Active Other Cash Flow0.080.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.080.000.000.000.000.000.000.000.00
Cash from Financing Activities8.604.758.943.4339.472.901.610.440.53
Exchange Rate Effect---1.040.470.18-0.02-0.00-0.010.01
Net Change in Cash2.91-1.42-5.56-5.5319.781.060.95-0.070.01
Free Cash Flow-5.35-5.51-14.18-8.86-5.44-1.83-0.66-0.50-0.53
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments13.756.919.129.3110.318.12
Short Term Receivables4.044.013.464.163.593.45
Inventories12.1213.1713.4714.0613.0211.86
Other Current Assets0.760.690.800.440.941.05
Total Current Assets30.6724.7826.8527.9727.8524.48
Net Property, Plant & Equipment1.131.231.341.421.531.42
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.841.921.892.012.493.19
Deferred Tax Assets--0.000.090.090.09
Other Assets0.000.000.000.000.000.00
Total Assets33.6327.9330.0831.4931.9729.19
Short Term Debt Incl. Current Port. of LT Debt0.200.210.220.220.220.21
Accounts Payable4.855.105.666.144.805.02
Income Tax Payable0.270.270.270.000.260.23
Other Current Liabilities0.300.300.300.300.300.30
Total Current Liabilities5.625.886.446.655.575.76
Long Term Debt0.480.540.600.640.710.72
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities6.096.417.047.296.286.48
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.010.010.010.010.010.01
Common Equity27.5321.5023.0324.1925.6722.69
Total Shareholders Equity27.5421.5223.0424.2025.6822.70
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity27.5421.5223.0424.2025.6822.70
Total Liabilities & Stockholders Equity33.6327.9330.0831.4931.9729.19
Book Value Per Share230.48876.63938.681,061.751,126.961,676.02
Tangible Book Value Per Share215.05798.45861.65973.541,017.611,440.14
Full-Time Employees--50---
Price to Book Ratio0.010.240.260.280.260.23
Return on Assets-17.78-21.15-19.71-19.47-20.59-16.47
Return on Equity-21.92-27.32-25.68-24.34-25.65-21.17
Return on Invested Capital-5.58-5.64-9.06-3.56-6.71-5.04
Quick Ratio3.301.982.082.092.662.19
Current Ratio5.464.224.174.205.004.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.56-1.24-2.14-0.88-1.77-1.18
Depreciation0.080.080.100.100.070.06
Other Funds (Non Cash)0.100.000.140.551.060.00
Funds from Operations-1.39-1.17-1.90-0.23-0.64-1.11
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.47-0.910.28-0.49-0.64-0.60
Income Taxes Payable-0.000.00-0.150.160.03-0.04
Cash from Operating Activities-0.92-2.07-1.62-0.73-1.27-1.71
Capital Expenditures-0.01-0.10-0.04-0.03-0.55-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.00-0.01-0.080.060.04
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.10-0.05-0.12-0.49-0.18
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock7.800.000.720.003.670.36
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.800.000.720.003.670.36
Proceedsfrom Stock Options5.080.000.000.001.830.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.08-0.06-0.02
Other Financing Activities Uses0.000.000.000.08-0.06-0.02
Cash from Financing Activities7.800.000.720.083.610.34
Exchange Rate Effect-0.05-0.03----0.01
Net Change in Cash6.84-2.21-1.04-0.671.86-1.56
Free Cash Flow-0.92-2.08-1.61-0.74-1.43-1.72

Revenue breakdown

Pharmaceutical Preparations2024: 34.87M 2025: 36.31M
United States2024: 34.87M 2025: 36.31M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30103.71%0.2M0.2M299.82K
2026-10-1525.25%0.0M0.2M272.02K
2026-09-303.11%0.0M0.2M25.92K
2026-09-150.64%0.0M0.2M25.93K
2026-08-312.48%0.0M0.2M37.60K
2026-08-142.11%0.0M0.2M93.56K
2026-07-315.77%0.0M0.1M81.68K
2026-07-152.85%0.0M0.1M81.47K
2026-06-305.82%0.0M0.1M79.82K
2026-06-158.40%0.0M0.1M77.58K
2026-05-296.94%0.0M0.1M65.62K
2026-05-1510.13%0.0M0.0M432
2026-04-302.17%0.0M0.0M179
2026-04-152.80%0.0M0.0M185
2026-03-312.86%0.0M0.0M187
2026-03-133.40%0.0M0.0M224
2026-02-274.61%0.0M0.0M217
2026-02-134.80%0.0M0.0M267
2026-01-305.74%0.0M0.0M330
2026-01-156.27%0.0M0.0M3.64K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-10-27DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-10-30SEC
2026-10-14SCHEDULE 13GSEC
2026-10-14PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-10-14SEC
2026-10-148-KCurrent report2026-10-13SEC
2026-10-13SCHEDULE 13GSEC
2026-10-098-KCurrent report2026-10-08SEC
2026-10-09424B4SEC
2026-10-07EFFECTEffectiveness filing by commission orderSEC
2026-10-05SCHEDULE 13G/ASEC
2026-10-02S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-28DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-09-15SEC
2026-09-24DRSSEC
2026-09-16PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-09-15SEC
2026-09-168-KCurrent report2026-09-15SEC
2026-09-118-KCurrent report2026-09-11SEC
2026-09-08EFFECTEffectiveness filing by commission orderSEC
2026-09-08424B3SEC
2026-08-28S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-288-KCurrent report2026-08-25SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-20424B5SEC
2026-07-208-KCurrent report2026-07-20SEC
2026-07-108-KCurrent report2026-07-08SEC
2026-07-08SCHEDULE 13GSEC
2026-06-08DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-06-08SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
UBS Group AG0.81%
JANE STREET GROUP, LLC0.71%
MORGAN STANLEY0.02%
SBI Securities Co., Ltd.0.00%
Caitong International Asset Management Co., Ltd0.00%
NATIONAL BANK OF CANADA /FI/0.00%
OSAIC HOLDINGS, INC.0.00%
Farther Finance Advisors, LLC0.00%
Strive Financial Group ,LLC0.00%
TD Waterhouse Canada Inc.0.00%

Funds

Fund% owned
-

OakChart. SBFM. Cached 15 minutes.

Some panels did not load: ratings, insider.